Cogent Biosciences will present the top‑line results of its Phase 3 PEAK trial at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The trial evaluated bezuclastinib in combination with sunitinib versus sunitinib alone in patients with advanced gastrointestinal stromal tumors (GIST) who had progressed on imatinib, and the oral presentation is scheduled for May 30 2026.
The November 2025 data showed a 50 % reduction in the risk of disease progression or death and a 46 % objective response rate versus 26 % for sunitinib monotherapy. These results represent a substantial improvement over the current standard of care and position bezuclastinib as a potential first new therapy for second‑line GIST in more than two decades.
Cogent’s presentation is a key step toward FDA approval. The company has already submitted a New Drug Application for bezuclastinib in non‑advanced systemic mastocytosis under the Real‑Time Oncology Review program, with a PDUFA target of December 30 2026. The NDA for GIST is expected to be completed in April 2026, aligning with the ASCO presentation.
Financially, Cogent reported a net loss of $328.9 million for 2025, largely driven by $269.8 million in R&D expenses. Cash, cash equivalents, and marketable securities totaled $900.8 million as of December 31 2025, giving the company a runway into 2028. In Q4 2025 the company posted a net loss of $102.5 million and an earnings per share of –$0.55.
President and CEO Andrew Robbins described the PEAK trial results as a "historic day" and emphasized that bezuclastinib could fill a long‑standing unmet need in second‑line GIST therapy.
The positive data and upcoming presentation are expected to generate significant interest from clinicians, payers, and investors, as the company moves closer to commercial launch. The trial’s success could broaden the addressable market for bezuclastinib and accelerate regulatory and reimbursement pathways.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.